A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cutaneous Warts

Trial Profile

A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cutaneous Warts

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Digoxin/furosemide (Primary) ; Digoxin; Furosemide
  • Indications Warts
  • Focus Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Cutanea Life Sciences
  • Most Recent Events

    • 01 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 04 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 05 Jan 2015 Planned primary completion date changed to 1 Sep 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top